Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc (ATXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,206
  • Shares Outstanding, K 1,431
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,380 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta -0.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.70 +30.82%
on 10/17/24
2.70 -17.63%
on 10/21/24
+0.15 (+7.18%)
since 10/04/24
3-Month
1.70 +30.82%
on 10/17/24
3.54 -37.18%
on 09/09/24
-0.40 (-15.11%)
since 08/02/24
52-Week
1.70 +30.82%
on 10/17/24
26.47 -91.60%
on 01/04/24
-16.54 (-88.15%)
since 11/03/23

Most Recent Stories

More News
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

FBIO : 1.7100 (-10.00%)
ATXI : 2.23 (-0.45%)
S&P Futures Climb as Investors Weigh Economic Outlook, U.S. Bank Earnings on Tap

June S&P 500 futures (ESM23) are trending up +0.34% this morning after three major U.S. benchmark indices ended the regular session higher as market participants digested the latest batch of corporate...

ESM23 : 4,453.35s (+0.61%)
SCHW : 70.61 (-0.47%)
RXDX : 199.92 (+0.09%)
STT : 92.75 (-0.05%)
GOOGL : 169.60 (-0.99%)
JNJ : 158.87 (-0.79%)
BAC : 41.37 (-0.93%)
NFLX : 759.32 (+0.43%)
LMT : 544.89 (-0.08%)
GS : 512.21 (-1.37%)
ERICB.S.DX : 89.420 (-0.07%)
ATXI : 2.23 (-0.45%)
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease

/PRNewswire/ -- AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the...

ATXI : 2.23 (-0.45%)
Pre-Market Brief: Stocks Mixed as Key U.S. Payrolls Data Looms

December S&P 500 futures (ESZ22) are trending down -0.12% this morning after three major US benchmark indices extended declines for the second successive trading session as investors digested remarks from...

ESZ22 : 3,871.47s (-0.66%)
AMD : 141.83 (-0.02%)
NVDA : 137.83 (+1.79%)
DKNG : 35.88 (+0.53%)
ATXI : 2.23 (-0.45%)
LEVI : 16.98 (-1.22%)
APRN : 12.99 (-0.08%)
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous...

ATXI : 2.23 (-0.45%)
Avenue Therapeutics Stock Trading Halted Today

FDA Advisory Committee to review IV tramadol New Drug Application...

ATXI : 2.23 (-0.45%)
Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)

NEW YORK, NY / ACCESSWIRE / December 15, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therapeutics...

ATXI : 2.23 (-0.45%)
Avenue Therapeutics Announces Closing of Public Offering of Common Stock

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of...

ATXI : 2.23 (-0.45%)
Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock

NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous...

ATXI : 2.23 (-0.45%)
Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous...

ATXI : 2.23 (-0.45%)

Business Summary

Avenue Therapeutics, Inc. is a specialty pharmaceutical company. It acquires, licenses, develops and commercializes products principally for use in the acute/intensive care hospital setting. Avenue Therapeutics, Inc. is based in New York, United States.

See More

Key Turning Points

3rd Resistance Point 2.72
2nd Resistance Point 2.60
1st Resistance Point 2.42
Last Price 2.23
1st Support Level 2.12
2nd Support Level 2.00
3rd Support Level 1.82

See More

52-Week High 26.47
Fibonacci 61.8% 17.01
Fibonacci 50% 14.08
Fibonacci 38.2% 11.16
Last Price 2.23
52-Week Low 1.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar